UNASSIGNED: @entity1 with @entity28 ( @entity28 ) do not present those @entity209 that define the @entity209 ( @entity209 ). Whether @entity28 is associated with lower impairment of vasoreactivity than the @entity209 is unknown. To this purpose, forearm blood flow (FBF) responses were measured by strain-gauge plethysmography during the intra-arterial infusion of @entity934 ( @entity3451 ), @entity1854 ( @entity4982 ), and/or the selective endothelin type A ( @entity2231 ) receptor blocker @entity11344 in 119 @entity28 individuals with @entity28 (n=34) or with the @entity209 (n=85) and in healthy lean controls (n=56). @entity3451 and of @entity4982 caused a significant vasodilation in both @entity28 and the lean @entity1 (all P<0.001). The response, however, to both agents was significantly lower in the @entity28 than in the control group (both P<0.001). Among the @entity28 @entity1 , the reactivity to @entity3451 , was higher in @entity28 than @entity209 @entity1 , whereas the responsiveness to @entity4982 was equally impaired in both groups (P=0.45). Infusion of @entity11344 significantly increased FBF in @entity28 @entity1 (P<0001), but not in the lean @entity1 , hence FBF increase following @entity2231 receptor blockade was higher in both @entity28 groups than in controls (P<0.001). FBF response to @entity11344 was significantly higher in @entity1 with the @entity209 than in those with @entity28 (p=0.007). In conclusion, @entity1 with @entity28 have abnormal vascular reactivity, albeit their @entity409 is less pronounced than in @entity1 with the @entity209 . These findings indicate that @entity28 is associated with @entity1504 independent of those @entity209 underlying the @entity209 .

Vasodilator Responses and Endothelin-Dependent Vasoconstriction in Metabolically Healthy Obesity and the XXXX .

@entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients'] @entity28 :: ('MESH:D009765', 'Disease') :: ['MHO', 'obesity', 'obese', 'metabolically healthy obesity'] @entity1854 :: ('MESH:D009599', 'Chemical') :: ['sodium nitroprusside'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity1504 :: ('MESH:D002561', 'Disease') :: ['vascular damage'] @entity4982 :: ('D009599', 'Chemical') :: ['SNP'] @entity11344 :: ('MESH:C072247', 'Chemical') :: ['BQ-123'] @entity3451 :: ('D000109', 'Chemical') :: ['ACh'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome', 'MetS', 'metabolic abnormalities'] @entity2231 :: ('1909', 'Gene') :: ['ETA'] @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']
@entity209 :: (MESH:D008659,Disease) :: ['Metabolic Syndrome']
